WuXi Biologics Reports Solid 2025 Interim Results
Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded by 3.6% YoY to 42.7% EBITDA grew 50.5% YoY and IFRS net ...
Will the strong adjusted EBITDA and net profit growth translate into higher dividend payouts or share buybacks, and what is the expected impact on the stock price trajectory?
What are the drivers behind the 50.5% YoY EBITDA increase and how sustainable are they compared to peers in the CDMO sector?
How will the 20.2% revenue growth from continuing operations and expanding gross margin affect WuXi Biologics' valuation multiples?
21 days ago